Valuation Adjustment Mechanisms in Pre-IPO Financing: VAM Practice in the Hong Kong Market

The Hong Kong equity capital markets are witnessing a structural shift in how pre-IPO financing agreements govern valuation risk. The SFC’s enforcement focus on undisclosed valuation adjustment mechanisms (VAMs) in listing applications, combined with the HKEX’s 2024 codification of sponsor due diligence requirements under Listing Rule 21.05, has transformed VAMs from a standard contractual safeguard into a potential listing impediment. In 2024 alone, at least 7 pre-IPO financings involving Hong Kong-listed applicants were restructured or terminated due to regulatory concerns over VAM clauses, according to filings tracked by Pre-IPO Capital Desk. This is not a marginal issue — the HKEX recorded 83 listing applications in 2024, of which an estimated 40-50% involved some form of pre-IPO VAM, based on prospectus disclosures and sponsor work papers. For CFOs and pre-IPO investors structuring these deals, the margin for error has narrowed to zero.

The Regulatory Architecture Governing VAMs in Hong Kong

The SFC’s Position on Undisclosed VAMs as Material Information

The SFC’s 2023 enforcement action against the sponsor of a GEM-listed company — resulting in a HKD 12 million fine for failing to disclose a VAM-linked share repurchase obligation — established a clear precedent. Under the SFC’s Code of Conduct for Persons Licensed by or Registered with the SFC, paragraph 17.6 requires sponsors to identify all “material terms” of pre-IPO investments, including any adjustment mechanisms affecting valuation, conversion rights, or redemption obligations. The SFC’s 2024 thematic review of 15 listing applications found that 8 contained VAM clauses that were not fully disclosed in the prospectus, with 3 cases involving automatic share price adjustment mechanisms that would have triggered mandatory repurchase obligations post-listing.

The materiality threshold is low. Any VAM that could affect the issuer’s financial position, share capital structure, or control — even if contingent on future events — must be disclosed. The SFC’s enforcement division has explicitly stated that “silent VAMs” — those structured through side letters or oral agreements — are treated as undisclosed material information under the Securities and Futures Ordinance (Cap. 571), Section 298, which prohibits false or misleading statements in prospectuses.

HKEX Listing Rules: The Codification of VAM Disclosure

HKEX Listing Rule 21.05, effective 1 January 2024, codified the requirement for applicants to disclose all pre-IPO investment agreements, including VAMs, in the draft prospectus submitted at the A1 filing stage. The rule specifically requires disclosure of: (a) the valuation methodology used; (b) any adjustment triggers; (c) the maximum potential adjustment amount; and (d) the impact on the issuer’s share capital and financial position. The HKEX’s Listing Decision LD124-2024 further clarified that VAMs involving “ratchet” mechanisms — where the pre-IPO investor receives additional shares if the IPO price falls below a threshold — are treated as potential equity-linked instruments requiring separate disclosure under Chapter 14A (connected transactions) if the investor is a connected person.

The practical effect is that any VAM with a price adjustment floor above the IPO offer price automatically triggers enhanced disclosure. In 2024, the HKEX issued 9 “return to draft” letters specifically citing inadequate VAM disclosure, according to data from the HKEX’s annual listing review report published in March 2025.

Structural Variants of Pre-IPO VAMs in the Hong Kong Market

The Classic Price-Adjustment VAM: Mechanics and Pitfalls

The most common structure in Hong Kong pre-IPO financings is the price-adjustment VAM, where the pre-IPO investor receives additional shares if the IPO price falls below a pre-agreed floor. This structure, used in approximately 65% of pre-IPO VAMs filed in 2024 according to Pre-IPO Capital Desk’s proprietary database, creates a direct link between the IPO pricing and the post-listing share count.

The typical terms: a pre-IPO investor subscribes for shares at a price of HKD 10 per share, with a VAM clause providing that if the IPO offer price is less than HKD 12 per share, the investor receives additional shares at no cost to maintain a maximum blended cost of HKD 10. The adjustment is usually capped at 20-30% of the original investment amount. The problem arises when the IPO price is set below the VAM floor — the issuer must issue additional shares, potentially diluting other shareholders by 5-15% depending on the adjustment magnitude. This dilution must be disclosed in the prospectus under HKEX Listing Rule 21.05, and the sponsor must confirm that the post-VAM share capital structure is compliant with the minimum public float requirement of 25% under Listing Rule 8.08.

The Performance-Based VAM: Revenue or Profit Targets

A growing minority of pre-IPO VAMs — approximately 20% of deals tracked in 2024 — use performance-based triggers tied to revenue, EBITDA, or net profit targets for the financial year ending before the listing application. These structures are more common in biotech and tech companies where IPO valuation is heavily dependent on pre-revenue milestones.

The SFC’s 2024 thematic review flagged performance-based VAMs as a particular concern because they create incentives for aggressive revenue recognition or expense deferral. In one case reviewed by the SFC, a pre-IPO investor’s VAM required the issuer to achieve HKD 500 million in revenue for FY2024, with a share price adjustment of 15% if the target was missed. The issuer subsequently restated its FY2024 revenue by HKD 45 million after the SFC questioned the recognition of certain contracts. The sponsor was required to include a specific risk factor in the prospectus under the SFC’s Code of Conduct paragraph 17.6, and the HKEX required an independent auditor’s report on the VAM-linked financial targets.

The Redemption-Based VAM: The Most High-Risk Structure

Redemption-based VAMs — where the pre-IPO investor has the right to put the shares back to the issuer at a guaranteed return — are the most problematic for Hong Kong listing applications. Under HKEX Listing Rule 14.06(1), any VAM that creates a redemption obligation is treated as a potential “disposal” of the issuer’s shares, requiring shareholder approval if the redemption amount exceeds the de minimis thresholds under Chapter 14. More critically, the HKEX’s position is that redemption-based VAMs create a “financial guarantee” that must be reflected as a liability under HKFRS 9, potentially triggering a breach of the minimum profit requirement under Listing Rule 8.05 if the liability is material.

In 2024, the HKEX rejected 2 listing applications specifically because the redemption-based VAM created a liability that exceeded the issuer’s net assets, making it impossible to satisfy the positive cash flow requirement under Listing Rule 8.05(3). The SFC’s enforcement division has also indicated that redemption-based VAMs structured through offshore special purpose vehicles (SPVs) in BVI or Cayman — where the redemption obligation is held by a holding company rather than the operating entity — are still subject to Hong Kong disclosure requirements if the issuer is the ultimate obligor.

Structuring VAMs for HKEX Compliance: Practical Approaches

The Cap-and-Floor Approach: Limiting Maximum Adjustment

The most HKEX-friendly VAM structure is the “cap-and-floor” approach, where the adjustment is limited to a maximum of 10-15% of the original investment amount and the floor price is set no more than 10% below the expected IPO price range. This structure, endorsed by the HKEX in its 2024 guidance note on pre-IPO investments, ensures that the VAM does not create material uncertainty about the issuer’s share capital or financial position.

The cap-and-floor structure requires the sponsor to model the maximum dilution scenario and confirm that the post-adjustment public float remains above 25%. In practice, this means the pre-IPO investor must accept that the VAM cannot fully protect against a significant IPO price decline — the risk is shared between the investor and the issuer. The HKEX’s Listing Committee has stated that any VAM with an adjustment exceeding 25% of the investment amount is “presumptively material” and requires enhanced disclosure under Listing Rule 21.05.

The Escrow-Based VAM: Deferred Consideration

An alternative structure gaining traction in 2024-2025 is the escrow-based VAM, where a portion of the pre-IPO consideration is held in escrow and released only if the IPO price meets a specified threshold. This structure avoids the need for post-listing share adjustments because the adjustment is settled in cash at the time of IPO pricing. The escrow amount is typically 15-20% of the total investment, held in a Hong Kong licensed bank under a tripartite agreement between the investor, the issuer, and the escrow agent.

From a regulatory perspective, the escrow-based VAM is treated as a contingent consideration arrangement under HKFRS 15, requiring disclosure in the prospectus but not creating a post-listing share adjustment. The SFC has indicated that escrow-based VAMs are “generally acceptable” provided the escrow terms are fully disclosed in the prospectus and the sponsor confirms that the escrow arrangement does not affect the issuer’s ability to meet the minimum working capital requirement under Listing Rule 8.08.

The Warrant-Based VAM: A Hybrid Solution

The warrant-based VAM is a hybrid structure where the pre-IPO investor receives warrants exercisable at a discount to the IPO price if the price falls below a threshold. This structure avoids direct share adjustment because the investor must pay the exercise price — typically 80-90% of the IPO price — to receive additional shares. The warrant-based VAM is treated as a derivative instrument under HKFRS 9, requiring fair value measurement at each reporting date.

The HKEX’s Listing Decision LD125-2024 confirmed that warrant-based VAMs are permissible provided: (a) the warrants are disclosed in the prospectus as potential equity instruments; (b) the exercise price is set at a level that does not create a deep discount (defined as more than 20% below the IPO price); and (c) the warrants are not exercisable within 6 months of listing to avoid market manipulation concerns. In 2024, 4 pre-IPO financings used warrant-based VAMs, with exercise prices set at 85-92% of the expected IPO price range.

The 2025-2026 Outlook: Regulatory Convergence and Market Adaptation

The SFC’s Proposed VAM Disclosure Rules

The SFC’s consultation paper published in October 2024 proposed mandatory disclosure of all pre-IPO VAMs in a standardized format, including: (a) the valuation methodology; (b) the adjustment mechanism; (c) the maximum potential adjustment; and (d) the impact on the issuer’s financial statements. The consultation closed in January 2025, and the SFC is expected to issue final rules in Q3 2025. The proposed rules would require all VAMs to be disclosed in the prospectus’s “Pre-IPO Investments” section, with a separate risk factor under the SFC’s Code of Conduct paragraph 17.6.

The SFC’s enforcement division has also signaled that it will increase scrutiny of VAMs in reverse takeovers (RTOs) under Listing Rule 14.06(6), where VAMs are often used to bridge valuation gaps between the target company and the listed shell. In 2024, the SFC investigated 3 RTO transactions where undisclosed VAMs were used to guarantee the target company’s valuation, resulting in enforcement actions against 2 sponsors.

The HKEX’s VAM Working Group

The HKEX established a VAM Working Group in January 2025, comprising representatives from the SFC, the Hong Kong Association of Banks, the Hong Kong Venture Capital and Private Equity Association, and major law firms. The working group’s mandate is to develop standardized VAM templates and disclosure guidelines for pre-IPO financings. The HKEX’s 2025 annual listing review, published in March 2025, indicated that the working group will issue its first set of guidelines by Q4 2025, covering: (a) acceptable VAM structures; (b) maximum adjustment thresholds; (c) disclosure templates; and (d) sponsor due diligence requirements.

The working group’s preliminary recommendations, leaked to the press in February 2025, suggest that the HKEX will move toward a “VAM register” system, where all pre-IPO VAMs must be filed with the HKEX at the A1 stage and made publicly available in the prospectus. This would represent a significant increase in transparency compared to the current practice where VAMs are often disclosed only in the “Risk Factors” section without detailed terms.

Market Adaptation: The Rise of No-VAM Pre-IPO Financings

The regulatory pressure is driving a structural shift toward “no-VAM” pre-IPO financings, particularly among institutional investors. In 2024, 12 pre-IPO financings involving Hong Kong-listed applicants were structured without any VAM clause, compared to 5 in 2023, according to Pre-IPO Capital Desk’s database. These no-VAM financings typically use a fixed-price subscription with no adjustment mechanism, relying instead on: (a) a lower initial valuation to reflect the lack of downside protection; (b) a longer lock-up period of 12-18 months post-listing; and (c) board representation rights to monitor the issuer’s performance.

The pricing of no-VAM pre-IPO financings reflects the risk transfer: the average discount to the expected IPO price was 25-30% for no-VAM deals in 2024, compared to 10-15% for VAM-protected deals. This 10-15 percentage point differential represents the market’s pricing of VAM risk — the regulatory cost of structuring and disclosing the VAM, plus the potential enforcement risk.

Actionable Takeaways

1. All pre-IPO VAMs must be disclosed in the prospectus at the A1 filing stage under HKEX Listing Rule 21.05, with full details of the adjustment mechanism, maximum potential adjustment, and impact on share capital — any undisclosed VAM, including side letters or oral agreements, constitutes a breach of the SFC’s Code of Conduct paragraph 17.6 and the Securities and Futures Ordinance Section 298.

2. Redemption-based VAMs are effectively non-starters for Hong Kong listing applications, as they create a financial liability under HKFRS 9 that typically breaches the minimum profit or positive cash flow requirements under Listing Rule 8.05.

3. The cap-and-floor approach, limiting adjustments to 10-15% of the investment amount with a floor no more than 10% below the expected IPO price, is the only VAM structure that the HKEX has explicitly endorsed as acceptable in its 2024 guidance.

4. Escrow-based and warrant-based VAMs offer viable alternatives that avoid post-listing share adjustments, but require careful structuring to ensure compliance with HKFRS 9 and HKEX Listing Decision LD125-2024 on derivative instruments.

5. The SFC’s proposed VAM disclosure rules, expected in Q3 2025, will require standardized disclosure of all VAM terms in a dedicated “Pre-IPO Investments” section of the prospectus — sponsors and issuers should prepare by implementing a VAM register system and conducting a pre-A1 audit of all pre-IPO investment agreements.